Gregory B. Melikyan

The paper characterizes structural, biophysical, and virological properties of HIV-1 capsid-targeting antivirals, showing improved potency and stability through chemical modifications of PF74.

This paper shows SERINC5 inhibits HIV-1 fusion by destabilizing small fusion pores in target or effector cells, independent of its presence in virions.

This study shows that CsA treatment sequesters IFITM proteins into intraluminal vesicles of late endosomes, reducing their antiviral activity by preventing viral fusion with the limiting membrane of these compartments.